Please login to the form below

Not currently logged in
Email:
Password:

Ergomed appoints Andrew Mackie as chief business officer

He is also inducted as executive director to the board

UK-based Ergomed has named Andrew Mackie as chief business officer and executive director to its board.

Mackie brings over 25 years of experience in pre clinical research, clinical and business development to the role and has held a number of senior R&D roles at Novartis and Sanofi. 

He joins from Lilly, where he was part of the business development team.

Miroslav Reljanovic, CEO at Ergomed, commented: “Over the past ten years, Andrew has worked with Ergomed as a consultant, and has been instrumental in developing the co-development business model, acting as lead negotiator on the partnerships signed to date. 

“His successful track record in drug development and deal making not only strengthens our capabilities as we continue to advance our co-development pipeline but ensures we have the right team in place as we look to expand through organic growth and acquisitions.”

After ten years in R&D, Mackie joined the UK biotech sector in 1997 at oncology specialist Antisoma, where he established the clinical development department and transitioned new molecules into development.

Ergomed provides specialised services to the pharma industry and the development of new drugs. 

6th July 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...